



Zyclara[®] (imiquimod) – First-time generic

- On August 21, 2018, Oceanside Pharmaceuticals launched an authorized generic version of Bausch Health's [Zyclara \(imiquimod\)](#) 3.75% cream pump.
- Zyclara 3.75% is indicated for the topical treatment of clinically typical visible or palpable, actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults and for the treatment of external genital and perianal warts (EGW)/condyloma acuminata in patients 12 years or older.
- Imiquimod is also available as the branded products: Zyclara 2.5% and Zyclara 3.75% cream in packets; and as the generic product [5% topical cream](#).
 - Zyclara 2.5% cream is indicated for AK, but not for EGW/condyloma acuminata.
 - The 5% cream is indicated for AK and EGW/condyloma acuminata.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.